Doz

Insulin aspart (rapid-acting)

انسولین آسپارت (سریع‌اثر)

⚠ Unverified

🍽️ Alimentary Tract And MetabolismRapid-acting insulin analogue

🤰 Pregnancy:Use with caution🤱 Breastfeeding:Use with caution👶 Children:Use with caution👴 Older adults:Use with caution 🇮🇷 Registered in Iran⛔ 1 contraindications 🇺🇸 FDA approved (BLA) BLA020986ATC A10AB05

Market / country: 🇺🇸 USA

NovoLog (US) · NovoRapid (GB)

🧮 Dose calculator

Type 1 diabetes · Regimen source: FDA NovoLog · 2

⛔ Label: individualise by route, metabolic needs, glucose monitoring and goals; SC 5–10 min before a meal. FDA NovoLog · 2

🛡️ Safety & information

Contraindications

  • ⛔ During hypoglycaemia; hypersensitivity to the insulin or excipients. FDA NovoLog · 4

Formulations

  • 100 units/mL (U-100) vial, PenFill or FlexPen — injection 🇺🇸 USA FDA NovoLog · 3

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA NovoLog · 8.1

    “Risk Summary Available information from published randomized controlled trials with insulin aspart use during the second trimester of pregnancy have not reported an association with insulin aspart and major birth defects or adverse maternal or fetal outcomes [see Data] .”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA NovoLog · 8.2

    “Risk Summary There are no data on the presence of NOVOLOG in human milk, the effects on the breastfed infant, or the effect on milk production.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA NovoLog · 8.4

    “The safety and effectiveness of NOVOLOG to improve glycemic control have been established in pediatric patients with diabetes mellitus.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA NovoLog · 8.5

    “Of the total number of patients (n=1,375) treated with NOVOLOG in 3 controlled clinical studies, 2.6% (n=36) were 65 years of age or over.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Inspired by the Saphira project; part of the content is taken from it.

Contact and correction requests — Telegram: @cenaav